Switch theme
Sign up to access all valuation multiples
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
2008
3.6K+
LTM Revenue $277M
LTM EBITDA -$146M
$3.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
RemeGen has a last 12-month revenue of $277M and a last 12-month EBITDA of -$146M.
In the most recent fiscal year, RemeGen achieved revenue of $138M and an EBITDA of -$160M.
RemeGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RemeGen valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $98.7M | $138M | XXX | XXX | XXX |
| Gross Profit | $174M | $64.0M | XXX | XXX | XXX |
| Gross Margin | 177% | 46% | XXX | XXX | XXX |
| EBITDA | -$104M | -$160M | XXX | XXX | XXX |
| EBITDA Margin | -105% | -116% | XXX | XXX | XXX |
| Net Profit | $35.5M | -$128M | XXX | XXX | XXX |
| Net Margin | 36% | -93% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, RemeGen's stock price is HKD 43 (or $6).
RemeGen has current market cap of HKD 23.4B (or $3.0B), and EV of HKD 25.5B (or $3.3B).
See RemeGen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.3B | $3.0B | XXX | XXX | XXX | XXX | $-0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, RemeGen has market cap of $3.0B and EV of $3.3B.
RemeGen's trades at 12.7x LTM EV/Revenue multiple, and -24.1x LTM EBITDA.
Analysts estimate RemeGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for RemeGen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.3B | XXX | XXX | XXX |
| EV/Revenue | 23.7x | XXX | XXX | XXX |
| EV/EBITDA | -20.4x | XXX | XXX | XXX |
| P/E | -15.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRemeGen's NTM/LTM revenue growth is 36%
RemeGen's revenue per employee for the last fiscal year averaged $38K, while opex per employee averaged $0.1M for the same period.
Over next 12 months, RemeGen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate RemeGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for RemeGen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -116% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 55% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -80% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $38K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 72% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 121% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 216% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RemeGen acquired XXX companies to date.
Last acquisition by RemeGen was XXXXXXXX, XXXXX XXXXX XXXXXX . RemeGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was RemeGen founded? | RemeGen was founded in 2008. |
| Where is RemeGen headquartered? | RemeGen is headquartered in Hong Kong. |
| How many employees does RemeGen have? | As of today, RemeGen has 3.6K+ employees. |
| Is RemeGen publicy listed? | Yes, RemeGen is a public company listed on HKG. |
| What is the stock symbol of RemeGen? | RemeGen trades under 09995 ticker. |
| When did RemeGen go public? | RemeGen went public in 2020. |
| Who are competitors of RemeGen? | Similar companies to RemeGen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of RemeGen? | RemeGen's current market cap is $3.0B |
| What is the current revenue of RemeGen? | RemeGen's last 12-month revenue is $277M. |
| What is the current EBITDA of RemeGen? | RemeGen's last 12-month EBITDA is -$146M. |
| What is the current EV/Revenue multiple of RemeGen? | Current revenue multiple of RemeGen is 12.7x. |
| What is the current EV/EBITDA multiple of RemeGen? | Current EBITDA multiple of RemeGen is -24.1x. |
| What is the current revenue growth of RemeGen? | RemeGen revenue growth between 2023 and 2024 was 40%. |
| Is RemeGen profitable? | Yes, RemeGen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
